Article tools
Author information

Research Article

Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss.

T Guyon, A Wakkach, S Poea, V Mouly, I Klingel-Schmitt, P Levasseur, D Beeson, O Asher, S Tzartos and S Berrih-Aknin

Centre National de la Recherche Scientifique ERS-566, 92350 Le Plessis-Robinson, France. t_guyon@hotmail.com

Published July 1, 1998

Myasthenia gravis (MG) is a neuromuscular disorder mediated by antibodies directed against the acetylcholine receptor (nAChR) resulting in a functional nAChR loss. To analyze the molecular mechanisms involved at the muscular target site, we studied the expression of nAChR subunits in muscle biopsy specimens from MG patients. By using quantitative PCR with an internal standard for each subunit, we found that the levels of beta-, delta-, and epsilon-subunit mRNA coding for the adult nAChR were increased in severely affected MG patients, matching our previous data on the alpha-subunit. Messenger levels were highly variable in MG patients but not in controls, pointing to individual factors involved in the regulation of nAChR genes. The fetal subunit (gamma-chain) transcripts were almost undetectable in the extrajunctional region of MG muscle, suggesting that gene regulation in MG differs from that in the denervation model, in which nAChR gamma-subunit mRNA is reexpressed. Nicotinic AChR loss mediated by monoclonal anti-nAChR antibodies in both the TE671 muscle cell line and cultured normal human myotubes induces a similar increase in beta- alphand delta-subunit mRNA levels, suggesting the existence of a new muscular signaling pathway system coupled to nAChR internalization and independent of muscle electrical activity. These data demonstrate the existence of a compensatory mechanism regulating the expression of the genes coding for the adult nAChR in patients with MG.

Articles that cite
this article:

Acetylcholine receptor-α subunit expression in myasthenia gravis: A role for the autoantigen in pathogenesis?
Jian Rong Sheng, Liang Cheng Li, Bellur S. Prabhakar, Matthew N. Meriggioli
Muscle Nerve 40(2):279. [CrossRef]

Treatment of Myasthenia Gravis by Preventing Acetylcholine Receptor Modulation
Mario Losen, Pilar Martínez-martínez, Marko Phernambucq, Janine Schuurman, Paul W.H.I. Parren, Marc H. De baets
Ann N Y Acad Sci 1132(1):174. [CrossRef]

Modulation of acetylcholine receptor expression in seronegative myasthenia gravis
Sandrine Poea, Thierry Guyon, Jocelyne Bidault, Corinne Bruand, Vincent Mouly, Sonia Berrih-aknin
Ann Neurol 48(5):696. [CrossRef]

Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders
M. Takamori, M. Motomura, T. Fukudome, H. Yoshikawa
Eur J Neurol 14(11):1230. [CrossRef]

Immunology of disorders of neuromuscular transmission
A. Vincent
Acta Neurol Scand 113(s183):1. [CrossRef]

Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis
Abderrahim Aissaoui, Isabelle Klingel-schmitt, Jacques Couderc, Danielle Chateau, Francois Romagne, Florence Jambou, Angela Vincent, Philippe Levasseur, Bruno Eymard, Marie Christine Maillot
Ann Neurol 46(4):559. [CrossRef]


Angela Vincent
Curr Opin Neurol 12(5):545. [CrossRef]

Acquired Disorders of the Neuromuscular Junction
Gilmore N. O??neill
Int Anesthesiol Clin 44(2):107. [CrossRef]

Advances in Neurobiology of the Neuromuscular Junction
Mohamed Naguib, Pamela Flood, Joseph J. Mcardle, H. R. Brenner
Anaesthesiology 96(1):202. [CrossRef]

Recent advances in the understanding and therapy of myasthenia gravis
Efrosini Fostieri, Kalliopi Kostelidou, Konstantinos Poulas, Socrates J Tzartos
Future Neurol 1(6):799. [CrossRef]